AI-genrated image of image-guided biopsy procedure
The global biopsy devices market is projected to grow from USD 2.33 billion in 2026 to USD 2.83 billion by 2031, registering a compound annual growth rate (CAGR) of 3.97%, according to a report by Mordor Intelligence.
The market’s growth is being driven by rising demand for early cancer diagnosis, wider adoption of image-guided biopsy procedures, and advances in minimally invasive tissue sampling technologies. Expanding diagnostic capabilities across healthcare facilities is also supporting market expansion.
Biopsy devices play a key role in diagnosing cancer and other abnormalities by enabling clinicians to collect tissue samples for histopathological examination and treatment planning. The report highlighted that hospitals, diagnostic and imaging centres, and ambulatory surgical centres are increasingly incorporating biopsy procedures into diagnostic pathways for breast, lung, prostate, colorectal and other conditions.
Technological improvements in needle-based instruments and vacuum-assisted biopsy systems are helping expand tissue sampling capabilities. Manufacturers are also developing devices compatible with advanced imaging platforms, alongside disposable products designed to support infection control and procedural efficiency.
Regional Outlook
North America holds the largest share of the biopsy devices market, supported by established healthcare infrastructure, advanced diagnostic imaging capabilities and broad access to cancer screening and diagnostic services.
Meanwhile, Asia-Pacific is emerging as a key growth region. Investments in healthcare infrastructure, rising awareness of early cancer detection and increasing demand for diagnostic services are creating opportunities for device manufacturers. China, Japan, India, South Korea and Australia are among the markets contributing to the region’s expanding oncology and diagnostic capabilities.
Key Trends Shaping the Biopsy Devices Market
The report identifies several key trends creating growth opportunities for biopsy device manufacturers. These include:
Growing adoption of image-guided biopsy procedures: Image-guided biopsy procedures are gaining importance as they enable clinicians to target suspicious tissue using imaging technologies such as ultrasound and computed tomography (CT). These techniques can facilitate sampling of lesions that may be difficult to access through conventional approaches.
Manufacturers are developing instruments compatible with advanced imaging systems to support accurate targeting and improve procedural workflows. Continued advances in imaging quality, navigation and device design are expected to contribute to the adoption of these procedures.
Integration of AI and navigation technologies: Artificial intelligence (AI) and advanced navigation technologies are creating opportunities to improve biopsy planning and lesion targeting. AI-assisted imaging tools can help clinicians analyse medical images and identify suspicious areas requiring further investigation, while navigation systems can support access to selected lesions.
Integrating these technologies into diagnostic workflows may help streamline procedures and support more consistent targeting. However, the report noted that wider adoption will depend on clinical validation, compatibility with existing systems and the ability of healthcare facilities to implement advanced technologies.
Expanding diagnostic infrastructure and outpatient procedures: The growth of diagnostic imaging centres and ambulatory surgical facilities is creating additional opportunities for biopsy device manufacturers. Healthcare providers increasingly require instruments that offer efficient workflows, straightforward setup and reliable tissue sampling across different care settings.
Manufacturers are responding with convenient devices and standardised procedure kits designed for use in outpatient and other clinical environments. However, equipment costs, training requirements and disparities in healthcare access may influence adoption across regions, the report said.
Major Companies in the Biopsy Devices Market
Key companies operating in the market include:
- Argon Medical Devices
- Cook Medical
- Hologic, Inc.
- Becton, Dickinson and Company
- Boston Scientific Corporation
